Eyenovia Q2 net loss narrows to $6.2M; first Mydcombi sale post-FDA approval

HYPERION DEFI, INC.

2023-Q2 EPS reported -$0.32

Net loss for Q2 2023 was $(6.2)M ($0.16 per share), improved from $(7.2)M ($0.22) in Q2 2022; cash $17.5M as of June 30.
First commercial sale of Mydcombi to Dr. Nathan Radcliffe; national launch expected in early 2024 after FDA approval.
Apersure (Microline) presbyopia program advances; FDA provided clear path; registration batch manufacture planned for Q4 2023.
R&D expenses $2.8M (down from $3.6M), G&A $3.1M (down from $3.5M); total op expenses $6.0M vs $7.1M YoY.
Added to Russell 2000 and 3000 indexes; licensing partners Bausch+Lomb and Arctic Vision enrolling Phase 3 trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HYPERION DEFI, INC. reported the second quarter ended June 30, 2023 results: net income approximately $(6.2) million, or $(0.16) per share, EPS $(0.16) per share.

Period: the second quarter ended June 30, 2023
Net income: approximately $(6.2) million, or $(0.16) per share
EPS: $(0.16) per share
Result: reported results

Exact text from the filing

On August 10, 2023, Eyenovia, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

HYPERION DEFI, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-089813

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.